This study investigates the treatment of advanced hepatopancreabiliary tumors. The condition includes pancreatic cancer, hepatocellular carcinoma (HCC), and biliary tract cancer (BTC).
The study evaluates how the combination of immunotherapy and propranolol, with or without chemotherapy, affects these conditions.
- Who can participate: Participants must be 18 years or older with a body weight over 30 kg. They should have advanced pancreatic adenocarcinoma, hepatocellular carcinoma, or biliary tract cancer that cannot be treated with surgery or local therapy.
- Study details: Participants will receive a combination of investigational medications and propranolol. A placebo, an inactive substance that looks like the investigational medicine but does not contain any medicine, may be used in this study.
How understandable was the trial content above?
Hard to understand
Easy to understand